Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib

Roberto Gallego-Pinazo, J Fernando Arevalo, Patricia Udaondo, Salvador García-Delpech, Rosa Dolz-Marco, Manuel Díaz-Llopis

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to determine the efficacy of an intraoperative intravitreal pegaptanib injection during phacoemulsification in preventing the development of pseudophakic cystoid macular edema (CME) following cataract surgery. Methods: This prospective, controlled pilot study was carried out at the Department of Ophthalmology, Nuevo Hospital Universitario y Politécnico La Fe, Valencia (Spain). Five hundred patients with cataract and healthy retina were included in the study. Patients were assigned in a 1:1 ratio to receive an intraoperative intravitreal pegaptanib injection (n=250) or not (control group, n=250) associated with standardized phacoemulsification surgery and postoperative treatment. Any surgical complication was considered as an exclusion criterion. The main outcome measure was the incidence of CME at 4 weeks postsurgery, defined as a central foveal thickness greater than 350μm as measured by spectral-domain optical coherence tomography with associated cystoid changes. Results: The incidence of CME by the fourth postoperative week was 0.4% (n=1) in the pegaptanib group and 4.4% (n=11) in the control group (P=0.009). Conclusions: Prophylactic use of intravitreal pegaptanib immediately after phacoemulsification was effective in preventing CME by the fourth postoperative week. The inclusion of intravitreal pegaptanib injection in the prophylaxis of pseudophakic CME will be considered for complicated cases in forthcoming studies.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalJournal of Ocular Pharmacology and Therapeutics
Volume28
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Macular Edema
Intravitreal Injections
Phacoemulsification
Cataract
Control Groups
Incidence
Optical Coherence Tomography
Ophthalmology
Spain
Retina
Outcome Assessment (Health Care)
pegaptanib

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Cite this

Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib. / Gallego-Pinazo, Roberto; Arevalo, J Fernando; Udaondo, Patricia; García-Delpech, Salvador; Dolz-Marco, Rosa; Díaz-Llopis, Manuel.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 28, No. 1, 01.02.2012, p. 65-68.

Research output: Contribution to journalArticle

Gallego-Pinazo, R, Arevalo, JF, Udaondo, P, García-Delpech, S, Dolz-Marco, R & Díaz-Llopis, M 2012, 'Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib', Journal of Ocular Pharmacology and Therapeutics, vol. 28, no. 1, pp. 65-68. https://doi.org/10.1089/jop.2011.0089
Gallego-Pinazo, Roberto ; Arevalo, J Fernando ; Udaondo, Patricia ; García-Delpech, Salvador ; Dolz-Marco, Rosa ; Díaz-Llopis, Manuel. / Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib. In: Journal of Ocular Pharmacology and Therapeutics. 2012 ; Vol. 28, No. 1. pp. 65-68.
@article{5469748610564b26bfae5ca3b823d8d4,
title = "Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib",
abstract = "Purpose: The purpose of this study was to determine the efficacy of an intraoperative intravitreal pegaptanib injection during phacoemulsification in preventing the development of pseudophakic cystoid macular edema (CME) following cataract surgery. Methods: This prospective, controlled pilot study was carried out at the Department of Ophthalmology, Nuevo Hospital Universitario y Polit{\'e}cnico La Fe, Valencia (Spain). Five hundred patients with cataract and healthy retina were included in the study. Patients were assigned in a 1:1 ratio to receive an intraoperative intravitreal pegaptanib injection (n=250) or not (control group, n=250) associated with standardized phacoemulsification surgery and postoperative treatment. Any surgical complication was considered as an exclusion criterion. The main outcome measure was the incidence of CME at 4 weeks postsurgery, defined as a central foveal thickness greater than 350μm as measured by spectral-domain optical coherence tomography with associated cystoid changes. Results: The incidence of CME by the fourth postoperative week was 0.4{\%} (n=1) in the pegaptanib group and 4.4{\%} (n=11) in the control group (P=0.009). Conclusions: Prophylactic use of intravitreal pegaptanib immediately after phacoemulsification was effective in preventing CME by the fourth postoperative week. The inclusion of intravitreal pegaptanib injection in the prophylaxis of pseudophakic CME will be considered for complicated cases in forthcoming studies.",
author = "Roberto Gallego-Pinazo and Arevalo, {J Fernando} and Patricia Udaondo and Salvador Garc{\'i}a-Delpech and Rosa Dolz-Marco and Manuel D{\'i}az-Llopis",
year = "2012",
month = "2",
day = "1",
doi = "10.1089/jop.2011.0089",
language = "English (US)",
volume = "28",
pages = "65--68",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib

AU - Gallego-Pinazo, Roberto

AU - Arevalo, J Fernando

AU - Udaondo, Patricia

AU - García-Delpech, Salvador

AU - Dolz-Marco, Rosa

AU - Díaz-Llopis, Manuel

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Purpose: The purpose of this study was to determine the efficacy of an intraoperative intravitreal pegaptanib injection during phacoemulsification in preventing the development of pseudophakic cystoid macular edema (CME) following cataract surgery. Methods: This prospective, controlled pilot study was carried out at the Department of Ophthalmology, Nuevo Hospital Universitario y Politécnico La Fe, Valencia (Spain). Five hundred patients with cataract and healthy retina were included in the study. Patients were assigned in a 1:1 ratio to receive an intraoperative intravitreal pegaptanib injection (n=250) or not (control group, n=250) associated with standardized phacoemulsification surgery and postoperative treatment. Any surgical complication was considered as an exclusion criterion. The main outcome measure was the incidence of CME at 4 weeks postsurgery, defined as a central foveal thickness greater than 350μm as measured by spectral-domain optical coherence tomography with associated cystoid changes. Results: The incidence of CME by the fourth postoperative week was 0.4% (n=1) in the pegaptanib group and 4.4% (n=11) in the control group (P=0.009). Conclusions: Prophylactic use of intravitreal pegaptanib immediately after phacoemulsification was effective in preventing CME by the fourth postoperative week. The inclusion of intravitreal pegaptanib injection in the prophylaxis of pseudophakic CME will be considered for complicated cases in forthcoming studies.

AB - Purpose: The purpose of this study was to determine the efficacy of an intraoperative intravitreal pegaptanib injection during phacoemulsification in preventing the development of pseudophakic cystoid macular edema (CME) following cataract surgery. Methods: This prospective, controlled pilot study was carried out at the Department of Ophthalmology, Nuevo Hospital Universitario y Politécnico La Fe, Valencia (Spain). Five hundred patients with cataract and healthy retina were included in the study. Patients were assigned in a 1:1 ratio to receive an intraoperative intravitreal pegaptanib injection (n=250) or not (control group, n=250) associated with standardized phacoemulsification surgery and postoperative treatment. Any surgical complication was considered as an exclusion criterion. The main outcome measure was the incidence of CME at 4 weeks postsurgery, defined as a central foveal thickness greater than 350μm as measured by spectral-domain optical coherence tomography with associated cystoid changes. Results: The incidence of CME by the fourth postoperative week was 0.4% (n=1) in the pegaptanib group and 4.4% (n=11) in the control group (P=0.009). Conclusions: Prophylactic use of intravitreal pegaptanib immediately after phacoemulsification was effective in preventing CME by the fourth postoperative week. The inclusion of intravitreal pegaptanib injection in the prophylaxis of pseudophakic CME will be considered for complicated cases in forthcoming studies.

UR - http://www.scopus.com/inward/record.url?scp=84856884588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856884588&partnerID=8YFLogxK

U2 - 10.1089/jop.2011.0089

DO - 10.1089/jop.2011.0089

M3 - Article

VL - 28

SP - 65

EP - 68

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1

ER -